Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473073 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TSHRSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL6742362 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TSHRSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL11128935 | 0.74 | MAOB (0.52) | ALDH1A1TSHRSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL2963738 | 0.71 | L3MBTL1 (0.42) | ALDH1A1TSHRMEN1KMT2ALMNA | |
| SCHEMBL7383502 | 0.70 | G6PC1 (0.50) | ALDH1A1TSHRMAOB | |
| SCHEMBL4631652 | 0.70 | GAA (0.43) | ALDH1A1TSHRCYP1A2L3MBTL1 | |
| Styrene SCHEMBL11584452 | 0.70 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL39946 | 0.69 | ESR1 (0.44) | ALDH1A1TSHRSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL9818045 | 0.69 | ESR1 (0.44) | ALDH1A1TSHRSMN1; SMN2CYP1A2MEN1 | |
| Benzene SCHEMBL27985319 | 0.69 | ESR1 (0.44) | ALDH1A1TSHRSMN1; SMN2CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-8614215-B2 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | MERCK SERONO SA (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| EP-2118076-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | Merck Serono S.A. (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-6645995-B2 | Dipeptidyl peptidase-IV (DPP-IV); treating type II diabetes in a human; amino acid amides of 2-cyanopyrrolidine | NOVO NORDISK A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS (DK) | 2002-08-01 | — | — | US | disclosed |
| US-5391757-A | Benzenesulfonyl carboxamide compounds intermediate compounds and methods of preparation thereof and use of said compounds and intermediate compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1995-02-21 | — | — | US | disclosed |
| US-5338883-A | Benzenesulfonyl carboxamide compounds intermediate compounds and methods of preparation thereof and use of said compounds and intermediate compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1994-08-16 | — | — | US | disclosed |
| US-4992094-A | Herbicides | AMERICAN CYANAMID COMPANY (US) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | ALDH1A1 577/4885TSHR 4726/4885SMN1; SMN2 3366/4885 |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | ALDH1A1 229/4885TSHR 2284/4885SMN1; SMN2 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.